Literature DB >> 27696270

New technologies - new insights into the pathogenesis of hepatic encephalopathy.

Luisa Baker1, Bernard Lanz2,3, Fausto Andreola4, Javier Ampuero5,6, Anisha Wijeyesekera7, Elaine Holmes7, Nicolaas Deutz8.   

Abstract

Hepatic encephalopathy (HE) is a neuropsychiatric syndrome which frequently accompanies acute or chronic liver disease. It is characterized by a variety of symptoms of different severity such as cognitive deficits and impaired motor functions. Currently, HE is seen as a consequence of a low grade cerebral oedema associated with the formation of cerebral oxidative stress and deranged cerebral oscillatory networks. However, the pathogenesis of HE is still incompletely understood as liver dysfunction triggers exceptionally complex metabolic derangements in the body which need to be investigated by appropriate technologies. This review summarizes technological approaches presented at the ISHEN conference 2014 in London which may help to gain new insights into the pathogenesis of HE. Dynamic in vivo 13C nuclear magnetic resonance spectroscopy was performed to analyse effects of chronic liver failure in rats on brain energy metabolism. By using a genomics approach, microRNA expression changes were identified in plasma of animals with acute liver failure which may be involved in interorgan interactions and which may serve as organ-specific biomarkers for tissue damage during acute liver failure. Genomics were also applied to analyse glutaminase gene polymorphisms in patients with liver cirrhosis indicating that haplotype-dependent glutaminase activity is an important pathogenic factor in HE. Metabonomics represents a promising approach to better understand HE, by capturing the systems level metabolic changes associated with disease in individuals, and enabling monitoring of metabolic phenotypes in real time, over a time course and in response to treatment, to better inform clinical decision making. Targeted fluxomics allow the determination of metabolic reaction rates thereby discriminating metabolite level changes in HE in terms of production, consumption and clearance.

Entities:  

Keywords:  Genomics; Hepatic encephalopathy; Metabonomics; MicroRNA; Nuclear magnetic resonance spectroscopy; Targeted fluxomics

Mesh:

Substances:

Year:  2016        PMID: 27696270     DOI: 10.1007/s11011-016-9906-y

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  45 in total

1.  Critical flicker frequency for quantification of low-grade hepatic encephalopathy.

Authors:  Gerald Kircheis; Matthias Wettstein; Lars Timmermann; Alfons Schnitzler; Dieter Häussinger
Journal:  Hepatology       Date:  2002-02       Impact factor: 17.425

2.  Decreased plasma and tissue isoleucine levels after simulated gastrointestinal bleeding by blood gavages in chronic portacaval shunted rats.

Authors:  S W Olde Damink; C H Dejong; N E Deutz; P B Soeters
Journal:  Gut       Date:  1997-03       Impact factor: 23.059

3.  Nitric oxide and L-arginine metabolism in a devascularized porcine model of acute liver failure.

Authors:  Vikram Sharma; Gabriella A M Ten Have; Lars Ytrebo; Sambit Sen; Christopher F Rose; R Neil Dalton; Charles Turner; Arthur Revhaug; Hans M H van-Eijk; Nicolaas E P Deutz; Rajiv Jalan; Rajeshwar P Mookerjee; Nathan A Davies
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-03-15       Impact factor: 4.052

4.  Variations in the promoter region of the glutaminase gene and the development of hepatic encephalopathy in patients with cirrhosis: a cohort study.

Authors:  Manuel Romero-Gómez; María Jover; José A Del Campo; José L Royo; Elena Hoyas; José J Galán; Carmina Montoliu; Eugenia Baccaro; Mónica Guevara; Juan Córdoba; Germán Soriano; José M Navarro; Carmen Martínez-Sierra; Lourdes Grande; Antonio Galindo; Emilia Mira; Santos Mañes; Agustín Ruiz
Journal:  Ann Intern Med       Date:  2010-09-07       Impact factor: 25.391

5.  Reduced citrulline production in sepsis is related to diminished de novo arginine and nitric oxide production.

Authors:  Yvette C Luiking; Martijn Poeze; Graham Ramsay; Nicolaas E P Deutz
Journal:  Am J Clin Nutr       Date:  2008-12-03       Impact factor: 7.045

6.  Value of critical flicker frequency and psychometric hepatic encephalopathy score in diagnosis of low-grade hepatic encephalopathy.

Authors:  Gerald Kircheis; Norbert Hilger; Dieter Häussinger
Journal:  Gastroenterology       Date:  2013-12-21       Impact factor: 22.682

7.  A reproducible, clinically relevant, intensively managed, pig model of acute liver failure for testing of therapies aimed to prolong survival.

Authors:  Karla C L Lee; Carolina Palacios Jimenez; Hatim Alibhai; Yu-Mei Chang; Pamela J Leckie; Luisa A Baker; Giacomo Stanzani; Simon L Priestnall; Rajeshwar P Mookerjee; Rajiv Jalan; Nathan A Davies
Journal:  Liver Int       Date:  2013-01-20       Impact factor: 5.828

Review 8.  In vivo 1H-[13C]-NMR spectroscopy of cerebral metabolism.

Authors:  Robin A de Graaf; Graeme F Mason; Anant B Patel; Kevin L Behar; Douglas L Rothman
Journal:  NMR Biomed       Date:  2003 Oct-Nov       Impact factor: 4.044

9.  Application of deuterium oxide (D2O) to metabolic research: just D2O it? Depends just how you D2O it!

Authors:  Daniel J Wilkinson; Philip J Atherton; Bethan E Phillips; Paul L Greenhaff; Kenneth Smith
Journal:  Am J Physiol Endocrinol Metab       Date:  2015-05-01       Impact factor: 4.310

10.  Circulating microRNAs Reveal Time Course of Organ Injury in a Porcine Model of Acetaminophen-Induced Acute Liver Failure.

Authors:  Luisa A Baker; Karla C L Lee; Carolina Palacios Jimenez; Hatim Alibhai; Yu-Mei Chang; Pamela J Leckie; Rajeshwar P Mookerjee; Nathan A Davies; Fausto Andreola; Rajiv Jalan
Journal:  PLoS One       Date:  2015-05-27       Impact factor: 3.240

View more
  1 in total

1.  Probiotics improve the neurometabolic profile of rats with chronic cholestatic liver disease.

Authors:  Veronika Rackayová; Emmanuelle Flatt; Olivier Braissant; Jocelyn Grosse; Daniela Capobianco; Paola Mastromarino; Matthew McMillin; Sharon DeMorrow; Valérie A McLin; Cristina Cudalbu
Journal:  Sci Rep       Date:  2021-01-26       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.